Similarly, high DDX17 expression leads to a worsened prognosis for patients with glioma (17), gastric cancer (149), pancreatic cancer (150), colon cancer (151), paclitaxel-resistant ovarian cancer (152), and other cancers. Here, DDX17 is linked to malignant colon neoplasm.